72.19.Z - Scientific research and development activities
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
46.46.Z - Wholesale trade of pharmaceutical and medical products
49.39.Z - Other land passenger transport, not elsewhere classified
70.22.Z - Head office activities and management consultancy
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.11.Z - Scientific research and development activities
86 - Healthcare
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | 6,3 | 2,3 | 4,4 | 93,1 |
Gross profit (loss) | 5 | 2,2 | 3,1 | 45,1 |
EBITDA | 5,8 | 2 | 4 | 98,8 |
Short time liabilities | 0,8 | 1,1 | 2,8 | 157,7 |
Other operating costs | 0,8 | 0,4 | 0,6 | 47,7 |
Equity capital | 6,7 | 8,4 | 10,7 | 27,7 |
Operating profit (EBIT) | 5,6 | 1,9 | 3,8 | 104,3 |
Assets | 11,7 | 9,5 | 14 | 47,4 |
Net profit (loss) | 3,9 | 1,7 | 2,3 | 35,9 |
Cash | 1,2 | 3,7 | 9 | 145,8 |
Net income from sale | 20,8 | 20,8 | 20,7 | -0,8 |
Liabilities and provisions for liabilities | 5 | 1,1 | 3,3 | 200,2 |
Working assets | 11,2 | 9 | 13,6 | 50,7 |
Other income costs | 0 | 0 | 0,1 | 337,2 |
Depreciation | 0,2 | 0,1 | 0,2 | 21,9 |
% | % | % | p.p. | |
Profitability of capital | 57,7 | 20,4 | 21,7 | 1,3 |
Equity capital to total assets | 57,2 | 88,6 | 76,7 | -11,9 |
Gross profit margin | 24,1 | 10,3 | 15,1 | 4,8 |
EBITDA Margin | 27,7 | 9,7 | 19,4 | 9,7 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 13 | 19 | 49 | 30 |
Current financial liquidity indicator | 14.523886680603027 | 8.378460884094238 | 4.898690223693848 | -3,5 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane